Search for: "US v. Isom" Results 61 - 80 of 93
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
6 Nov 2019, 11:30 am by John Elwood
(relisted after the October 11, October 18 and November 1 conferences) Isom v. [read post]
20 May 2009, 5:18 am
BIO Policy Briefing raises the IP social media question (PatentlyBIOtech) Vietnam: Patentability of medical use claims in Vietnam (RelatIP)   Products Actonel (Risedronic) – US: CAFC affirms Procter & Gamble’s Actonel patent validity; nonobviousness of positional isomer: Procter & Gamble v Teva (Patent Docs) (Patently-O) (SmartBrief) (SmartBrief) (GenericsWeb) Alimta (Pemetrexed) – US: Eli Lilly and… [read post]
14 Nov 2019, 8:09 am by John Elwood
Mann, 18-1477, and National Review, Inc. v. [read post]
19 Sep 2010, 4:06 pm
My query is whether data exclusivity of 10 years will apply to new products or not like isomer dugs ex: arformoterol, armodafinil, dexlansoprazole etc… These drugs got three years exclusivity in US. [read post]
3 Mar 2011, 2:33 pm by James Bickford
At Monday’s oral argument in DePierre v. [read post]
6 Nov 2017, 2:04 pm by Kenneth Vercammen Esq. Edison
(a) Except as provided in subsection (g) of this section, a person who operates a motor vehicle while under the influence of intoxicating liquor, narcotic, hallucinogenic or habit-producing drug, or operates a motor vehicle with a blood alcohol concentration of 0.08% or more by weight of alcohol in the defendant's blood or permits another person who is under the influence of intoxicating liquor, narcotic, hallucinogenic or habit-producing drug to operate a motor vehicle owned by him or in his… [read post]